Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event (REDUCE-Lipid)

Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event (REDUCE) : All Comers Study

Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD).

Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the first-line lipid-lowering therapy (LLT). However, a significant portion of patients did not attain their LDL-C goal in our locality. Statin no adherence, low uptake of adjuvant non-statin LLT, and therapeutic inertia are few potential causes for not achieving the LDL-C target. ESC recommends repeating blood test in 6-8 weeks after addition or alternation of LLT, but this recommendation was not routinely followed in current local practice due to resources constrain.

This registry therefore aims to investigate the strategy of frequent monitoring of LDL-C and titration of LLT in achieving LDL-C treatment target at a dedicated specialist clinic.

Study Overview

• Status: Recruiting
• Conditions: Hyperlipidemia; Cardio Vascular Disease

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

• Study Contact: Name: Guangming Tan; Phone Number: 852-35051518; Email: xjldaniel@gmail.com

Study Locations

• Hong Kong
  • New Terrritories
    • Shatin, New Terrritories, Hong Kong, 999077
      • Recruiting
      • Prince of Wales Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients aged greater than 18 and who are admitted for a diagnosis of acute coronary syndrome (ACS) due to atherosclerotic coronary artery disease based on invasive coronary angiography will be recruited into this registry.

Description

Inclusion Criteria:

• Age >18
• (Cohort 1) Diagnosis of acute coronary syndrome due to atherosclerotic coronary artery disease
• (Cohort 2) Diagnosis of chronic coronary syndrome due to atherosclerotic coronary artery disease

Exclusion Criteria:

• Inability to provide valid consent by the patient or his legal guardian
• Diagnosis of ACS due to other causes than atherosclerotic coronary artery disease.
• Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy < 6 months.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Acute Coronary Syndrome; Patient with acute coronary syndrome due to atherosclerotic coronary artery disease
Chronic coronary syndrome; Patient with chronic coronary syndrome due to atherosclerotic coronary artery disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Low-density lipoprotein cholesterol (LDL-C) level	Absolute change in low-density lipoprotein cholesterol (LDL-C) level at baseline	Baseline
Low-density lipoprotein cholesterol (LDL-C) level	Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 8	week 8
Low-density lipoprotein cholesterol (LDL-C) level	Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 26	Week 26
Low-density lipoprotein cholesterol (LDL-C) level	Absolute change in low-density lipoprotein cholesterol (LDL-C) level at week 52	Week 52
Low-density lipoprotein cholesterol (LDL-C) level	Percentage change in low-density lipoprotein cholesterol (LDL-C) level at Baseline	Baseline
Low-density lipoprotein cholesterol (LDL-C) level	Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 8	Week 8
Low-density lipoprotein cholesterol (LDL-C) level	Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 26	Week 26
Low-density lipoprotein cholesterol (LDL-C) level	Percentage change in low-density lipoprotein cholesterol (LDL-C) level at week 52	Week 52

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of subject meeting LDL-C target	Proportion of patients meeting prespecified LDL-C goals (>50% reduction from baseline) at week 26.	Week 26
Rate of subject meeting LDL-C target	Proportion of patients meeting prespecified LDL-C goals (<1.4mmol/l) at week 26.	Week 26
Rate of subject meeting LDL-C target	Proportion of patients meeting prespecified LDL-C goals (<1.8mmol/L) at week 26.	Week 26
12-Item Short Form Survey (SF-12)	Patient's quality of life as measured by SF-12 at baseline	Baseline
12-Item Short Form Survey (SF-12)	Patient's quality of life as measured by SF-12 at week 8	Week 8
12-Item Short Form Survey (SF-12)	Patient's quality of life as measured by SF-12 at week 26	Week 26
12-Item Short Form Survey (SF-12)	Patient's quality of life as measured by SF-12 at week 52	Week 52
Rate of major adverse cardiovascular event (MACE)	Occurrence of any major adverse cardiovascular event (MACE) at Baseline	Baseline
Rate of major adverse cardiovascular event (MACE)	Occurrence of any major adverse cardiovascular event (MACE) at week 8	Week 8
Rate of major adverse cardiovascular event (MACE)	Occurrence of any major adverse cardiovascular event (MACE) at week 26	Week 26
Rate of major adverse cardiovascular event (MACE)	Occurrence of any major adverse cardiovascular event (MACE) at week 52	Week52
Modification of lipid lowering therapy (LLT)	Modification of lipid lowering therapy (LLT) at week 8	Week 8
Modification of lipid lowering therapy (LLT)	Modification of lipid lowering therapy (LLT) at week 26	Week 26
Modification of lipid lowering therapy (LLT)	Modification of lipid lowering therapy (LLT) at week 52	Week 52
Lipid Lowering Therapy adherence	LLT adherence, expressed in proportion of days covered, at week 52	Week 52
Tolerability of Lipid Lowering Therapy	Rate of adverse drug event reported by subjects on lipid lowering therapy at week 52	Week 52

Collaborators and Investigators

• Sponsor: Chinese University of Hong Kong

Study record dates

Study Major Dates

• Study Start (Actual): December 30, 2024
• Primary Completion (Estimated): December 31, 2030
• Study Completion (Estimated): June 30, 2031

Study Registration Dates

• First Submitted: December 17, 2025
• First Submitted That Met QC Criteria: December 17, 2025
• First Posted (Actual): December 31, 2025

Study Record Updates

• Last Update Posted (Actual): December 31, 2025
• Last Update Submitted That Met QC Criteria: December 17, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Dyslipidemias; Lipid Metabolism Disorders; Nutritional and Metabolic Diseases; Hyperlipidemias
• Other Study ID Numbers: 2024.356

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No